Please enable JavaScript to continue using this application.

Compare $CHRS vs $CMPX | Chartloom

Compare

$CHRS vs $CMPX

Coherus Oncology Inc · Compass Therapeutics Inc.

CHRS

Coherus Oncology Inc

CMPX

Compass Therapeutics Inc.

Compare $CHRS vs $CMPX

Comparing Coherus Oncology Inc and Compass Therapeutics Inc.

CHRSCoherus Oncology Inc

CMPXCompass Therapeutics Inc.

CHRSCoherus Oncology Inc

Market cap

$165M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

2.04x

Rev growth (TTM)

-64.3%

YTD performance

-21.9%

52W performance

-39.2%

FCF yield

-112.7%

CMPXCompass Therapeutics Inc.

Market cap

$179M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

1.51x

Rev growth (TTM)

—

YTD performance

-80.8%

52W performance

-74.5%

FCF yield

-31.5%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CHRS

CMPX

Detailed metrics comparison

CHRS

Coherus Oncology Inc

CMPX

Compass Therapeutics Inc.

Market Cap

CHRS$165M

CMPX$179M

Enterprise Value

CHRS$134M

CMPX$143M

Price

CHRS$1.07

CMPX$0.99

P/E Ratio

CHRSN/A

CMPXN/A

P/S Ratio

CHRS3.24x

CMPX0.00x

EV/Sales

CHRS2.63x

CMPX0.00x

EV/EBITDA

CHRS2.57x

CMPX0.00x

P/B Ratio

CHRS2.95x

CMPX0.93x

P/FCF Ratio

CHRSN/A

CMPXN/A

EV/FCF

CHRS-0.72x

CMPX-2.54x

PEG Ratio

CHRSN/A

CMPXN/A

Forward P/E (NTM)

CHRSN/A

CMPXN/A

Forward P/S (NTM)

CHRS2.04x

CMPX1.51x

Revenue (TTM)

CHRS$51M

CMPX$0

Revenue Growth (YoY)

CHRS-64.3%

CMPXN/A

Forward Rev Growth

CHRS67.8%

CMPX397.5%

Gross Margin (TTM)

CHRS68.9%

CMPX0.0%

Operating Margin (TTM)

CHRS0.0%

CMPX0.0%

EBITDA Margin (TTM)

CHRS-288.0%

CMPX0.0%

Net Margin (TTM)

CHRS-259.4%

CMPX0.0%

FCF Margin (TTM)

CHRS-365.2%

CMPXN/A

Net Income (TTM)

CHRS$-132M

CMPX$-30M

FCF (TTM)

CHRS$-186M

CMPX$-56M

EPS (TTM)

CHRS-$0.85

CMPX$0.00

ROE (TTM)

CHRS-18336.0%

CMPX-2994.0%

ROA (TTM)

CHRS-4290.0%

CMPX-2635.0%

ROIC (TTM)

CHRS-10716.0%

CMPX-2994.0%

Cash

CHRS$83M

CMPX$35M

Debt

CHRS$52M

CMPX$0

Net Cash/Debt

CHRS$31M

CMPX$35M

Current Ratio (TTM)

CHRS1.77x

CMPX11.22x

Quick Ratio (TTM)

CHRS1.58x

CMPX11.15x

Debt/Equity (TTM)

CHRS0.85x

CMPX0.00x

Debt/Assets (TTM)

CHRS0.0%

CMPX0.0%

Interest Coverage (TTM)

CHRSN/A

CMPXN/A

Net Debt/EBITDA (TTM)

CHRS0.00x

CMPX0.00x

Beta

CHRS0.99

CMPX1.07

52W Performance

CHRS-39.2%

CMPX-74.5%

YTD Performance

CHRS-21.9%

CMPX-80.8%

% from 52W High

CHRS-59.1%

CMPX-85.6%

% from 52W Low

CHRS9.9%

CMPX19.7%

Asset Turnover (TTM)

CHRS0.17x

CMPX0.00x

FCF Yield (TTM)

CHRS-112.7%

CMPX-31.5%

Earnings Yield (TTM)

CHRS-80.1%

CMPX-16.8%

Dividend Yield (TTM)

CHRSN/A

CMPXN/A

Rule of 40

CHRS-429.5

CMPX0.0

EV/GP/RG

CHRS0.05

CMPXN/A

Ticker research

View CHRS research View CMPX research

Metric	CHRS Coherus Oncology Inc	CMPX Compass Therapeutics Inc.
Market & Valuation
Market Cap	$165M	$179M
Enterprise Value	$134M	$143M
Price	$1.07	$0.99
P/E Ratio	N/A	N/A
P/S Ratio	3.24x	0.00x
EV/Sales	2.63x	0.00x
EV/EBITDA	2.57x	0.00x
P/B Ratio	2.95x	0.93x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.72x	-2.54x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	2.04x	1.51x
Revenue & Growth
Revenue (TTM)	$51M	$0
Revenue Growth (YoY)	-64.3%	N/A
Forward Rev Growth	67.8%	397.5%
Profitability
Gross Margin (TTM)	68.9%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-288.0%	0.0%
Net Margin (TTM)	-259.4%	0.0%
FCF Margin (TTM)	-365.2%	N/A
Net Income (TTM)	$-132M	$-30M
FCF (TTM)	$-186M	$-56M
EPS (TTM)	-$0.85	$0.00
ROE (TTM)	-18336.0%	-2994.0%
ROA (TTM)	-4290.0%	-2635.0%
ROIC (TTM)	-10716.0%	-2994.0%
Financial Health
Cash	$83M	$35M
Debt	$52M	$0
Net Cash/Debt	$31M	$35M
Current Ratio (TTM)	1.77x	11.22x
Quick Ratio (TTM)	1.58x	11.15x
Debt/Equity (TTM)	0.85x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.99	1.07
52W Performance	-39.2%	-74.5%
YTD Performance	-21.9%	-80.8%
% from 52W High	-59.1%	-85.6%
% from 52W Low	9.9%	19.7%
Efficiency & Yields
Asset Turnover (TTM)	0.17x	0.00x
FCF Yield (TTM)	-112.7%	-31.5%
Earnings Yield (TTM)	-80.1%	-16.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-429.5	0.0
EV/GP/RG	0.05	N/A
Ticker research	View CHRS research	View CMPX research

Valuation

P/S Ratio

CMPX

0.00x

CHRS

3.24x

EV/FCF

CMPX

-2.54x

CHRS

-0.72x

Growth & revenue

Revenue Growth TTM

CHRS

-64.3%

Forward Revenue Growth

CMPX

397.5%

CHRS

67.8%

Profitability & performance

Gross Margin

CHRS

68.9%

CMPX

0.0%

ROE

CMPX

-2994.0%

CHRS

-18336.0%

FCF Yield %

CMPX

-31.5%

CHRS

-112.7%

52-Week Performance

CHRS

-39.2%

CMPX

-74.5%

Detailed metrics comparison

CHRS

Coherus Oncology Inc

CMPX

Compass Therapeutics Inc.

Market Cap

CHRS$165M

CMPX$179M

Enterprise Value

CHRS$134M

CMPX$143M

Price

CHRS$1.07

CMPX$0.99

P/E Ratio

CHRSN/A

CMPXN/A

P/S Ratio

CHRS3.24x

CMPX0.00x

EV/Sales

CHRS2.63x

CMPX0.00x

EV/EBITDA

CHRS2.57x

CMPX0.00x

P/B Ratio

CHRS2.95x

CMPX0.93x

P/FCF Ratio

CHRSN/A

CMPXN/A

EV/FCF

CHRS-0.72x

CMPX-2.54x

PEG Ratio

CHRSN/A

CMPXN/A

Forward P/E (NTM)

CHRSN/A

CMPXN/A

Forward P/S (NTM)

CHRS2.04x

CMPX1.51x

Revenue (TTM)

CHRS$51M

CMPX$0

Revenue Growth (YoY)

CHRS-64.3%

CMPXN/A

Forward Rev Growth

CHRS67.8%

CMPX397.5%

Gross Margin (TTM)

CHRS68.9%

CMPX0.0%

Operating Margin (TTM)

CHRS0.0%

CMPX0.0%

EBITDA Margin (TTM)

CHRS-288.0%

CMPX0.0%

Net Margin (TTM)

CHRS-259.4%

CMPX0.0%

FCF Margin (TTM)

CHRS-365.2%

CMPXN/A

Net Income (TTM)

CHRS$-132M

CMPX$-30M

FCF (TTM)

CHRS$-186M

CMPX$-56M

EPS (TTM)

CHRS-$0.85

CMPX$0.00

ROE (TTM)

CHRS-18336.0%

CMPX-2994.0%

ROA (TTM)

CHRS-4290.0%

CMPX-2635.0%

ROIC (TTM)

CHRS-10716.0%

CMPX-2994.0%

Cash

CHRS$83M

CMPX$35M

Debt

CHRS$52M

CMPX$0

Net Cash/Debt

CHRS$31M

CMPX$35M

Current Ratio (TTM)

CHRS1.77x

CMPX11.22x

Quick Ratio (TTM)

CHRS1.58x

CMPX11.15x

Debt/Equity (TTM)

CHRS0.85x

CMPX0.00x

Debt/Assets (TTM)

CHRS0.0%

CMPX0.0%

Interest Coverage (TTM)

CHRSN/A

CMPXN/A

Net Debt/EBITDA (TTM)

CHRS0.00x

CMPX0.00x

Beta

CHRS0.99

CMPX1.07

52W Performance

CHRS-39.2%

CMPX-74.5%

YTD Performance

CHRS-21.9%

CMPX-80.8%

% from 52W High

CHRS-59.1%

CMPX-85.6%

% from 52W Low

CHRS9.9%

CMPX19.7%

Asset Turnover (TTM)

CHRS0.17x

CMPX0.00x

FCF Yield (TTM)

CHRS-112.7%

CMPX-31.5%

Earnings Yield (TTM)

CHRS-80.1%

CMPX-16.8%

Dividend Yield (TTM)

CHRSN/A

CMPXN/A

Rule of 40

CHRS-429.5

CMPX0.0

EV/GP/RG

CHRS0.05

CMPXN/A

Ticker research

View CHRS research View CMPX research

Metric	CHRS Coherus Oncology Inc	CMPX Compass Therapeutics Inc.
Market & Valuation
Market Cap	$165M	$179M
Enterprise Value	$134M	$143M
Price	$1.07	$0.99
P/E Ratio	N/A	N/A
P/S Ratio	3.24x	0.00x
EV/Sales	2.63x	0.00x
EV/EBITDA	2.57x	0.00x
P/B Ratio	2.95x	0.93x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.72x	-2.54x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	2.04x	1.51x
Revenue & Growth
Revenue (TTM)	$51M	$0
Revenue Growth (YoY)	-64.3%	N/A
Forward Rev Growth	67.8%	397.5%
Profitability
Gross Margin (TTM)	68.9%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-288.0%	0.0%
Net Margin (TTM)	-259.4%	0.0%
FCF Margin (TTM)	-365.2%	N/A
Net Income (TTM)	$-132M	$-30M
FCF (TTM)	$-186M	$-56M
EPS (TTM)	-$0.85	$0.00
ROE (TTM)	-18336.0%	-2994.0%
ROA (TTM)	-4290.0%	-2635.0%
ROIC (TTM)	-10716.0%	-2994.0%
Financial Health
Cash	$83M	$35M
Debt	$52M	$0
Net Cash/Debt	$31M	$35M
Current Ratio (TTM)	1.77x	11.22x
Quick Ratio (TTM)	1.58x	11.15x
Debt/Equity (TTM)	0.85x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.99	1.07
52W Performance	-39.2%	-74.5%
YTD Performance	-21.9%	-80.8%
% from 52W High	-59.1%	-85.6%
% from 52W Low	9.9%	19.7%
Efficiency & Yields
Asset Turnover (TTM)	0.17x	0.00x
FCF Yield (TTM)	-112.7%	-31.5%
Earnings Yield (TTM)	-80.1%	-16.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-429.5	0.0
EV/GP/RG	0.05	N/A
Ticker research	View CHRS research	View CMPX research